Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide

Prostate

Volumn 76, Issue 16, 2016, Pages 1484-1490

  Markowski, Mark C ^a   Frick, Kevin D ^b   Eshleman, James R ^a,c   Luo, Jun ^c   Antonarakis, Emmanuel S ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AR V7 testing; CLIA certified; cost savings; healthcare costs; prostate cancer

Indexed keywords

ABIRATERONE; ENZALUTAMIDE; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; AR PROTEIN, HUMAN; BIOLOGICAL MARKER; BRIDGED COMPOUND; ISOPROTEIN; PHENYLTHIOHYDANTOIN; TAXANE; TAXOID;

AR V7 ASSAY; ARTICLE; ASSAY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CONTROLLED STUDY; COST CONTROL; DRUG COST; HEALTH CARE COST; HUMAN; HUMAN CELL; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; ANALOGS AND DERIVATIVES; COST; DRUG RESISTANCE; ECONOMICS; GENETICS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROSTENES; BIOMARKERS; BRIDGED-RING COMPOUNDS; COST SAVINGS; COSTS AND COST ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; TAXOIDS;

EID: 84991648558     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23232     Document Type: Article

References (26)

1. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009; 27(13):2111–2113.
2. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68(13):5469–5477.
3. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69(1):16–22.
4. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011; 6(4):e19059.
5. Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep 2015; 5:7654.
6. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371(11):1028–1038.
7. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015.
8. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher M, Dittamore R. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016. doi: 10.1001/jamaoncol.2016.1828
9. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015; 1(5):582–591.
10. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 2015; 26(9):1859–1865.
11. Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 2015; 68(6):939–945.
12. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C-A-. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21):1995–2005.
13. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, Investigators C-A-. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368(2):138–148.
14. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Investigators A. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13):1187–1197.
15. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, Investigators P. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(5):424–433.
16. Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw 2014; 12(10):1417–1425.
17. Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, Yu D, Srinivas S. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract 2014; 20(6):417–425.
18. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working G. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26(7):1148–1159.
19. Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: Estimates using a dynamic progression model. PLoS ONE 2015; 10(10):e0139440.
20. Kantarjian H, Steensma D, Rius Sanjuan J, Elshaug A, Light D. High cancer drug prices in the United States: Reasons and proposed solutions. J Oncol Pract 2014; 10(4):e208–e211.
21. Steensma DP, Kantarjian HM. Impact of cancer research bureaucracy on innovation, costs, and patient care. J Clin Oncol 2014; 32(5):376–378.
22. Dusetzina SB, Keating NL. Mind the gap: Why closing the doughnut hole is insufficient for increasing medicare beneficiary access to oral chemotherapy. J Clin Oncol 2016; 34(4):375–380.
23. Ramsey SD, Lyman GH, Bangs R. Addressing skyrocketing cancer drug prices comes with tradeoffs: Pick your poison. JAMA Oncol 2016; 2(4):425–426.
24. Goldberg T, Berrios-Colon E. Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer. Pharm Ther 2013; 38(1):23–26.
25. Pal SK, Stein CA, Sartor O. Enzalutamide for the treatment of prostate cancer. Expert Opin Pharmacothe 2013; 14(5):679–685.
26. Guirgis HM. The value of anticancer drugs in metastatic castrate-resistant prostate cancer: Economic tools for the community oncologist. J Community Support Oncol 2015; 13(10):362–366.